Resolutions of the Annual General Meeting of Evotec AG
June 17 2014 - 10:07AM
- Actions of Management Board and Supervisory Board
approved
- New Supervisory Board elected: Prof. Dr Wolfgang
Plischke new Chairman of the Supervisory Board
- Authorised Capital 2014 created
Evotec AG (Frankfurt:EVT) (TecDAX) (ISIN:DE0005664809) today
announced that its shareholders approved all proposals the
Company's Management put to vote at the Company's Annual General
Meeting.
The Chief Executive Officer of Evotec AG, Dr Werner Lanthaler,
presented the Company's performance for the year 2013 and provided
the shareholders with an update on the topic "Execute &
Innovate 20 years of Research – 20 years of Evotec."
At the Annual General Meeting, the actions of the members of the
Management Board and the Supervisory Board for the fiscal year 2013
were approved. Furthermore, a new Supervisory Board was elected by
the Annual General Meeting. The term of the new Supervisory Board
ends with the close of the Annual General Meeting charged with
approving the actions of the members of the Supervisory Board in
the 2018 fiscal year. Prof. Dr Wolfgang Plischke, former member of
the Management Board of Bayer AG, Prof. Dr Iris Löw-Friedrich,
Chief Medical Officer and Executive Vice President of UCB S.A., and
Prof. Dr Paul Linus Herrling, former global Head of Research of
Novartis Pharma AG and Chairman of the Board of the Novartis
Institute for Tropical Diseases joined the Supervisory Board as new
members. Three former members of the Supervisory Board, Dr Walter
Wenninger, Dr Claus Braestrup and Bernd Hirsch, were re-elected as
members of the new Supervisory Board of Evotec.
In a subsequent meeting of the Supervisory Board, Prof. Dr
Wolfgang Plischke was elected as Chairman of the Supervisory Board
and Dr Walter Wenninger, former Chairman of the Supervisory
Board of Evotec, was elected as his Vice Chairman.
"I'd like to express my sincere gratitude to the parting members
of the Supervisory Board, Mary Tanner, Roland Oetker and Prof. Dr
Andreas Pinkwart, also on behalf of my colleagues in the Management
Board, for their constructive and successful collaboration over the
last years," said Dr Werner Lanthaler, Chief Executive
Officer of Evotec. "At the same time, I'd like to thank
the remaining members of the Supervisory Board for their continued
commitment and warmly welcome Prof. Dr Iris Löw-Friedrich, Prof. Dr
Wolfgang Plischke and Prof. Dr Paul Linus Herrling to the
Supervisory Board of Evotec AG."
The Annual General Meeting also approved the proposal of the
Management Board and the Supervisory Board to create a new
Authorised Capital 2014. Moreover, the Annual General Meeting
passed the other agenda items requiring shareholders' approval,
hereunder the resolution on single amendments of the Articles of
Association and the appointment of Ernst & Young GmbH
Wirtschaftsprüfungsgesellschaft, Hamburg, as the auditor for fiscal
year 2014.
At the ordinary Annual General Meeting 2014 of Evotec AG, 34.9%
of the voting capital was present.
About Evotec AG
Evotec is a drug discovery alliance and development partnership
company focused on rapidly progressing innovative product
approaches with leading pharmaceutical and biotechnology companies.
We operate worldwide providing the highest quality stand-alone and
integrated drug discovery solutions, covering all activities from
target-to-clinic. The Company has established a unique position by
assembling top-class scientific experts and integrating
state-of-the-art technologies as well as substantial experience and
expertise in key therapeutic areas including neuroscience, pain,
metabolic diseases as well as oncology and inflammation. Evotec has
long-term discovery alliances with partners including Bayer,
Boehringer Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals,
MedImmune/AstraZeneca and Ono Pharmaceutical. In addition, the
Company has existing development partnerships and product
candidates both in clinical and pre-clinical development. These
include partnerships with Boehringer Ingelheim, MedImmune and
Andromeda (Teva) in the field of diabetes, with Janssen
Pharmaceuticals in the field of depression and with Roche in the
field of Alzheimer's disease. For additional information please go
to www.evotec.com.
FORWARD LOOKING STATEMENTS — Information set
forth in this press release contains forward-looking statements,
which involve a number of risks and uncertainties. The
forward-looking statements contained herein represent the judgement
of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to
a variety of risks and uncertainties, many of which are beyond our
control, and which could cause actual results to differ materially
from those contemplated in these forward-looking statements. We
expressly disclaim any obligation or undertaking to release
publicly any updates or revisions to any such statements to reflect
any change in our expectations or any change in events, conditions
or circumstances on which any such statement is based.
CONTACT: For further information, please contact
Gabriele Hansen
VP, Corporate Communications & Investor Relations
+49.(0)40.560 81-255
+49.(0)40.560 81-333 Fax
gabriele.hansen@evotec.com
Evotec AG
Manfred Eigen Campus
Essener Bogen 7
22419 Hamburg (Germany)
Eaton Vance Tax Advantag... (NYSE:EVT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Eaton Vance Tax Advantag... (NYSE:EVT)
Historical Stock Chart
From Jul 2023 to Jul 2024